vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and VinFast Auto Ltd. (VFS). Click either name above to swap in a different company.
ALNYLAM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($1.2B vs $718.6M, roughly 1.6× VinFast Auto Ltd.). ALNYLAM PHARMACEUTICALS, INC. runs the higher net margin — 17.6% vs -2.8%, a 20.4% gap on every dollar of revenue.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
VinFast Auto Ltd. is a Vietnamese multinational automotive company founded by Vingroup, one of the largest private conglomerates in Vietnam that was founded by Phạm Nhật Vượng.
ALNY vs VFS — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $718.6M |
| Net Profit | $206.0M | $-20.0M |
| Gross Margin | 82.2% | — |
| Operating Margin | 23.0% | -96.1% |
| Net Margin | 17.6% | -2.8% |
| Revenue YoY | 96.4% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.51 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | $718.6M | ||
| Q2 25 | $773.7M | $663.0M | ||
| Q1 25 | $594.2M | $656.5M | ||
| Q4 24 | $593.2M | — | ||
| Q3 24 | $500.9M | $511.6M | ||
| Q2 24 | $659.8M | — |
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | — | ||
| Q3 25 | $251.1M | $-20.0M | ||
| Q2 25 | $-66.3M | $-51.8M | ||
| Q1 25 | $-57.5M | $-26.1M | ||
| Q4 24 | $-83.8M | — | ||
| Q3 24 | $-111.6M | $-10.4M | ||
| Q2 24 | $-16.9M | — |
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | — | ||
| Q3 25 | 29.5% | -96.1% | ||
| Q2 25 | -2.1% | -79.0% | ||
| Q1 25 | 3.0% | -74.0% | ||
| Q4 24 | -17.7% | — | ||
| Q3 24 | -15.4% | -65.9% | ||
| Q2 24 | 7.4% | — |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | — | ||
| Q3 25 | 20.1% | -2.8% | ||
| Q2 25 | -8.6% | -7.8% | ||
| Q1 25 | -9.7% | -4.0% | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -22.3% | -2.0% | ||
| Q2 24 | -2.6% | — |
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | — | ||
| Q3 25 | $1.84 | — | ||
| Q2 25 | $-0.51 | — | ||
| Q1 25 | $-0.44 | — | ||
| Q4 24 | $-0.66 | — | ||
| Q3 24 | $-0.87 | — | ||
| Q2 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $8.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | — |
| Total Assets | $5.1B | $183.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.5B | $8.8M | ||
| Q2 25 | $1.1B | $650.0M | ||
| Q1 25 | $1.0B | $2.4M | ||
| Q4 24 | $966.4M | — | ||
| Q3 24 | $1.1B | $1.9M | ||
| Q2 24 | $968.5M | — |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | — | ||
| Q3 25 | $233.9M | — | ||
| Q2 25 | $250.6M | $-7.2B | ||
| Q1 25 | $115.4M | — | ||
| Q4 24 | $67.1M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $-3.1M | — |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | — | ||
| Q3 25 | $4.9B | $183.2M | ||
| Q2 25 | $4.6B | $7.2B | ||
| Q1 25 | $4.2B | $158.2M | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $4.2B | $151.8M | ||
| Q2 24 | $4.0B | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
VFS
| Sales of vehicles | $662.9M | 92% |
| Sales of spare parts and components | $41.3M | 6% |
| Revenue from leasing activities | $12.3M | 2% |
| Finance income | $2.4M | 0% |
| Rendering of services | $1.2M | 0% |
